Branch retinal vein occlusion

SightMD Welcomes Matthew Karl, MD to its expert team in New York

Retrieved on: 
Monday, August 28, 2023
Ohio State University, Macular degeneration, Georgetown, OH, Eye, SUNY Downstate Medical Center, Georgetown University, Retinal, Branch retinal vein occlusion, MD, Patient, Ophthalmology, Diabetic retinopathy, Paratriathlon, Health, Family, Fashion design, Growth

HAUPPAUGE, N.Y., August 28, 2023 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Matthew Karl, MD to its expert team.

Key Points: 
  • SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Matthew Karl, MD to its expert team.
  • HAUPPAUGE, N.Y., August 28, 2023 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Matthew Karl, MD to its expert team.
  • Dr. Matthew Karl is a board certified ophthalmologist and a fellowship trained vitreoretinal surgeon.
  • SightMD is actively seeking ophthalmology professionals who are interested in joining our outstanding team.

Dr. Deepika Malik: A Leading Vitreoretinal Surgeon Joins OCLI Vision, Offering Exceptional Eye Care Services

Retrieved on: 
Thursday, June 1, 2023
Faculty, Learning, Retinal detachment, Branch retinal vein occlusion, University, American Board of Ophthalmology, Associate professor, University of California, Irvine Medical Center, Philadelphia College of Osteopathic Medicine, Hindi, American Academy, Drexel University College of Medicine, Retina, Research, American Medical Association, Public key certificate, Osteopathy, American Board of Commissioners for Foreign Missions, MD, Patient, Diabetic retinopathy, SVP, Society, Nursing, Medical device, Ophthalmology

MINEOLA, N.Y., June 1, 2023 /PRNewswire-PRWeb/ -- Deepika Malik, MD, a highly experienced and fellowship-trained vitreoretinal surgeon, is ecstatic to join the OCLI Vision team, offering expert eye care services to patients in Rockland County, Orange County, and the boroughs of Queens, Manhattan, and Brooklyn. With her expertise in macular disorders, including age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, inflammatory ocular diseases, and surgical retinal diseases, Dr. Malik has built a well-respected name in the realm of ophthalmology.

Key Points: 
  • OCLI Vision, a Spectrum Vision Partners (SVP) managed practice, has announced the addition of Deepika Malik, MD, an esteemed Vitreoretinal Surgeon with experience spanning 15 years .
  • Dr. Malik is a Diplomate of the American Board of Ophthalmology and is Board Certified in Ophthalmology.
  • She completed her surgical vitreoretinal fellowship at Gavin Herbert Eye Institute at the University of California, Irvine.
  • With Dr. Malik's expert care, patients can trust that their eye health is in great hands.

Diabetic Retinopathy Pipeline Research Report 2022: Featuring Insights on 60+ Companies and Drugs in the Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 8, 2023
Pharmaceutical, Health, Optical, Route, Physician, Diabetic retinopathy, News, Edema, VEGF, Growth, Clinical trial, Fragment crystallizable region, Discovery, Injection, Administration, Anti-VEGF, AMD, NAV, Patient, Therapy, Ischemia, Drug development, Route of administration, Cerebral edema, GameChanger, Branch retinal vein occlusion, Pharmaceutical industry, Vaccine, Brolucizumab

Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with diabetic retinopathy.

Key Points: 
  • Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with diabetic retinopathy.
  • This segment of the report provides insights about the different Diabetic Retinopathy drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • The companies which have their Diabetic Retinopathy drug candidates in the mid to advanced stage, i.e.
  • Phase III include, Kodiak Sciences
    Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Retina Group of New England Joins Retina Consultants of America

Retrieved on: 
Friday, December 30, 2022
Optical, Health, Clinical Trials, Practice Management, Honor Award, Acral lentiginous melanoma, Partnership, RCA, MD, Research, Chowdhury, Multimedia, Consultant, Publication, Patient, DRS, Yale School of Medicine, Central University, ASRS, Learning, Physician, Diabetic retinopathy, Branch retinal vein occlusion, Distinguished Honor Award, Society, Yale school, Television, Medicine, Pharmaceutical industry, Retina, Ophthalmology

Retina Consultants of America (RCA), a comprehensive physician management services organization, announces the welcoming of Retina Group of New England (RGNE) into its nationwide network of physicians.

Key Points: 
  • Retina Consultants of America (RCA), a comprehensive physician management services organization, announces the welcoming of Retina Group of New England (RGNE) into its nationwide network of physicians.
  • This addition will be RCA’s 30th partnership and will break ground for RCA in Connecticut, to now operate in 20 states across the U.S.
  • View the full release here: https://www.businesswire.com/news/home/20221230005026/en/
    Dr. Nauman Chaudhry, MD, and Dr. Juner M. Colina-Biscotto, MD, of Retina Group of New England partner with Retina Consultants of America.
  • (Photo: Business Wire)
    “The doctors of Retina Group of New England are excited to join the ranks of highly accomplished and nationally recognized physicians and business team of RCA,” said Dr. Nauman Chaudhry, Retina Group of New England.

Diabetic Retinopathy Drug Pipeline Market Insights Report 2022 - Comprehensive Insights About 60+ Companies and 60+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
Diabetes, Health, Other Health, Diabetic retinopathy, Clinical trial, Injection, NAV, Route, News, Route of administration, Drug development, Branch retinal vein occlusion, Discovery, II, Edema, Cerebral edema, Ischemia, Fragment crystallizable region, Administration, VEGF, Physician, Therapy, Growth, AMD, GameChanger, Patient, Oil, Pharmaceutical industry, Brolucizumab

This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Diabetic Retinopathy pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Diabetic Retinopathy pipeline landscape.
  • This segment of the Diabetic Retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The companies which have their Diabetic Retinopathy drug candidates in the mid to advanced stage, i.e.
  • Phase III include, Kodiak Sciences
    Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

LSO Medical Announces CE Approval of Next-Gen LUMESEAL Laser for Treatment of Varicose Vein.

Retrieved on: 
Tuesday, September 21, 2021
Mark (given name), Marketing, LSO, Patient, SAS, Branch retinal vein occlusion, EVLT, 3D printing, Pharmaceutical industry

LILLE, France, Sept. 21, 2021 /PRNewswire/ -- LSO MEDICAL SAS, international leader in vascular laser therapies, announced today the CE Approval of its newest generation EVLT SnakeBack assisted system, the LUMESEAL laser platform.

Key Points: 
  • LILLE, France, Sept. 21, 2021 /PRNewswire/ -- LSO MEDICAL SAS, international leader in vascular laser therapies, announced today the CE Approval of its newest generation EVLT SnakeBack assisted system, the LUMESEAL laser platform.
  • The third-generation laser system incorporates the same 1470nm laser design combined with the RINGLIGHT fibers range design which has shown superior performance and clinical evidence compared to other alternative configurations.
  • With more than 20 years' experience, the French company LSO Medical is a key player in the design, production and marketing of innovative medical laser systems.
  • Constantly aiming at exploiting and bringing technological innovations to doctors and their patients, LSO Medical is today one of the world leaders in the endothermic laser technique.

LSO Medical Announces CE Approval of Next-Gen LUMESEAL Laser for Treatment of Varicose Vein.

Retrieved on: 
Tuesday, September 21, 2021
Mark (given name), Marketing, LSO, Patient, SAS, Branch retinal vein occlusion, EVLT, 3D printing, Pharmaceutical industry

LILLE, France, Sept. 21, 2021 /PRNewswire/ -- LSO MEDICAL SAS, international leader in vascular laser therapies, announced today the CE Approval of its newest generation EVLT SnakeBack assisted system, the LUMESEAL laser platform.

Key Points: 
  • LILLE, France, Sept. 21, 2021 /PRNewswire/ -- LSO MEDICAL SAS, international leader in vascular laser therapies, announced today the CE Approval of its newest generation EVLT SnakeBack assisted system, the LUMESEAL laser platform.
  • The third-generation laser system incorporates the same 1470nm laser design combined with the RINGLIGHT fibers range design which has shown superior performance and clinical evidence compared to other alternative configurations.
  • With more than 20 years' experience, the French company LSO Medical is a key player in the design, production and marketing of innovative medical laser systems.
  • Constantly aiming at exploiting and bringing technological innovations to doctors and their patients, LSO Medical is today one of the world leaders in the endothermic laser technique.

Virtual KOL Roundtable Recap: Outlook Therapeutics and Firas Rahhal, MD, Discussed wet AMD Treatment Landscape and ONS-5010/LYTENAVA™

Retrieved on: 
Wednesday, November 11, 2020
Ophthalmology, Clinical medicine, Organ systems, Orphan drugs, Angiogenesis inhibitors, Blindness, Macular edema, Macular degeneration, Bevacizumab, Diabetic retinopathy, Branch retinal vein occlusion, Central retinal vein occlusion

The Roundtable opened with a discussion of current treatment options for retinal diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).

Key Points: 
  • The Roundtable opened with a discussion of current treatment options for retinal diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).
  • ONS-5010, if approved, will be the first and only on-label ophthalmic formulation of bevacizumab-vikg for the treatment of wet AMD.
  • The Roundtable concluded with an update from Outlook Therapeutics management on the current clinical development program and anticipated commercialization strategy for ONS-5010/LYTENAVA.
  • Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD.